ADME毒理學檢測市場規模、佔有率和成長分析（按方法、技術、應用、最終用戶和地區分類）—產業預測（2026-2033年）

預計 2024 年 ADME 毒性測試市場規模將達到 116.5 億美元，從 2025 年的 130.5 億美元成長到 2033 年的 323.1 億美元，在預測期（2026-2033 年）內複合年成長率為 12%。

ADME毒性測試市場對於評估各種物質的藥物動力學和藥物動力學至關重要，能夠提供吸收、分佈、代謝和排泄過程的重要資訊。在法規結構日益嚴格的背景下，安全有效的藥物需求不斷成長，ADME測試在早期藥物開發和非臨床安全性評估中發揮關鍵作用。製藥公司和研究人員利用ADME測試來識別潛在毒性並表徵候選藥物的藥物動力學特徵。然而，人體生理的複雜性、個體差異以及適應不斷變化的法規等挑戰可能會影響試管內的準確性。同時，體外和電腦模擬方法的進步以及個人化醫療的應用，正在為市場創造巨大的機遇，並凸顯了藥物開發中對安全性和有效性的持續重視。

ADME毒性測試市場促進因素

ADME毒性測試市場的成長主要得益於製藥業對藥物研發日益成長的重視，而對創新療法的需求至關重要。致力於發現和開發針對各種疾病的有效療法的機構越來越依賴毒性測試，以確保候選藥物符合安全性和有效性標準。這項嚴格的評估流程對於製藥公司和研究機構至關重要，它能夠檢驗化合物在進入臨床試驗之前以及最終上市前的安全性和有效性，確保病患安全和符合監管要求。

限制 ADME 毒性測試市場的因素

ADME毒性測試市場面臨著巨大的經濟負擔，這主要源於測試過程涉及多種調查方法、專用設備以及合格人員的專業技能。對於預算較為緊張的中小型製藥公司而言，這些成本尤其阻礙因素。因此，高昂的毒性測試費用會抑制這些公司對關鍵研發舉措的投入，從而扼殺創新，並降低其在對安全性評估要求嚴格的市場中的競爭力。

ADME毒性測試市場趨勢

ADME毒性測試市場正日益受到體外和電腦模擬調查方法進步的推動，這些方法為傳統的動物試驗提供了高效、經濟且符合倫理的替代方案。創新體外檢測方法與先進預測建模技術的結合，正在提高毒性評估的準確性和可靠性。這些技術突破不僅簡化了藥物研發流程，也滿足了監管機構和社會對人道研究方法的需求。隨著各組織尋求提升其毒性評估能力，這些前沿方法的應用預計將顯著影響ADME毒性測試市場的未來模式。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球 ADME 毒性測試市場規模（按方法論和複合年成長率分類）（2026-2033 年）

• 細胞分析
• 生化分析
• In silico
• Ex-vivo

全球ADME毒理學檢測市場規模（依技術及複合年成長率分類）（2026-2033年）

• 細胞培養
• 高通量
• 分子影像
• 體學技術

全球 ADME 毒理學檢測市場規模（按應用及複合年成長率分類）（2026-2033 年）

• 全身毒性
• 腎毒性
• 肝毒性
• 神經毒性
• 其他

全球 ADME 毒性測試市場規模（按最終用戶和複合年成長率分類）（2026-2033 年）

• 醫院和診所
• 診斷中心
• 病理檢查室
• 其他

全球 ADME 毒理學檢測市場規模（按地區分類）及複合年成長率（2026-2033 年）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Charles River Laboratories（USA）
• Eurofins Scientific（Luxembourg）
• WuXi AppTec（China）
• SGS SA（Switzerland）
• PPD（USA）
• Covance Inc.（USA）
• ICON plc（Ireland）
• LabCorp（USA）
• Syneos Health（USA）
• IQVIA（USA）
• Boehringer Ingelheim（Germany）
• Merck & Co.（USA）
• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• AstraZeneca（UK）
• GlaxoSmithKline plc（UK）
• Sanofi（France）
• Johnson & Johnson（USA）
• AbbVie Inc.（USA）
• Eli Lilly and Company（USA）

結論與建議

ADME Toxicology Testing Market size was valued at USD 11.65 Billion in 2024 and is poised to grow from USD 13.05 Billion in 2025 to USD 32.31 Billion by 2033, growing at a CAGR of 12% during the forecast period (2026-2033).

The ADME toxicology testing market is essential for evaluating the pharmacokinetics and toxicokinetics of various substances, offering critical insights into absorption, distribution, metabolism, and elimination processes. This testing is pivotal in early-stage drug development and preclinical safety assessments, addressing the increasing demand for safer, more efficient pharmaceuticals amid rigorous regulatory frameworks. Pharmaceutical companies and researchers utilize ADME testing to identify potential toxicity and characterize pharmacokinetic profiles of drug candidates. However, challenges such as human physiological complexity, interindividual variations, and the need to adapt to evolving regulations can impact test accuracy. Conversely, advancements in in vitro and in silico methodologies, along with personalized medicine applications, present significant opportunities within the market, highlighting a continued emphasis on safety and efficacy in drug development.

Top-down and bottom-up approaches were used to estimate and validate the size of the ADME Toxicology Testing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

ADME Toxicology Testing Market Segments Analysis

Global ADME Toxicology Testing Market is segmented by Method, Technology, Application, End Users and region. Based on Method, the market is segmented into Cellular Assay, Biochemical Assay, In Silica and Ex-vivo. Based on Technology, the market is segmented into Cell Culture, High Throughput, Molecular Imaging and OMICS Technology. Based on Application, the market is segmented into Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity and Others. Based on End Users, the market is segmented into Hospitals and clinics, Diagnostic centers, Pathological Labs and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the ADME Toxicology Testing Market

The growth of the ADME Toxicology Testing market is significantly influenced by the increasing emphasis on drug development within the pharmaceutical industry, where the demand for innovative therapeutic solutions is paramount. As organizations strive to discover and create effective treatments for a wide range of health conditions, there is an escalating reliance on toxicology testing to ensure that drug candidates meet safety and efficacy standards. This rigorous evaluation process is essential for pharmaceutical companies and research institutions as they seek to validate their compounds prior to entering clinical trials and ultimately launching products into the market, ensuring patient safety and regulatory compliance.

Restraints in the ADME Toxicology Testing Market

The ADME Toxicology Testing market faces challenges due to the substantial financial burden linked to the testing processes, which encompass a range of experimental methodologies, specialized equipment, and the expertise of qualified personnel. These expenses can be particularly restrictive for smaller and medium-sized pharmaceutical firms that operate within tighter budget constraints. As a result, the high costs associated with comprehensive toxicology testing hinder the ability of these companies to invest in critical research and development initiatives, potentially stalling innovation and limiting their competitive capability in a market that demands rigorous safety assessments.

Market Trends of the ADME Toxicology Testing Market

The ADME Toxicology Testing market is increasingly driven by advancements in in vitro and in silico testing methodologies, which present efficient, cost-effective, and ethical alternatives to traditional animal testing. The integration of innovative in vitro assays and sophisticated predictive modeling techniques is enhancing the accuracy and reliability of toxicology evaluations. These technological breakthroughs not only streamline the drug development process but also align with the growing regulatory and societal demand for humane research practices. As organizations seek to improve their toxicology assessment capabilities, the adoption of these cutting-edge methods is expected to shape the future landscape of the ADME Toxicology Testing market significantly.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global ADME Toxicology Testing Market Size by Method & CAGR (2026-2033)

• Market Overview
• Cellular Assay
• Biochemical Assay
• In Silica
• Ex-vivo

Global ADME Toxicology Testing Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Cell Culture
• High Throughput
• Molecular Imaging
• OMICS Technology

Global ADME Toxicology Testing Market Size by Application & CAGR (2026-2033)

• Market Overview
• Systemic Toxicity
• Renal Toxicity
• Hepatotoxicity
• Neurotoxicity
• Others

Global ADME Toxicology Testing Market Size by End Users & CAGR (2026-2033)

• Market Overview
• Hospitals and clinics
• Diagnostic centers
• Pathological Labs
• Others

Global ADME Toxicology Testing Market Size & CAGR (2026-2033)

• North America (Method, Technology, Application, End Users)
  • US
  • Canada
• Europe (Method, Technology, Application, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Method, Technology, Application, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Method, Technology, Application, End Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Method, Technology, Application, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Charles River Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SGS SA (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PPD (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Covance Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LabCorp (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IQVIA (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations